Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:42:11.434Z.
Calculation as of: 2026-10-06T14:42:11.434Z.
Quote observation: 2026-10-06T14:39:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Werewolf Therapeutics, Inc.
Market Cap
$44.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$45.37M
EV/EBITDA Ratio
N/A
TTM Avg
14.42x
3Y Avg
17.44x
5Y Avg
22.72x
Market Cap
$44.16M
EV/EBITDA Ratio
N/A
TTM Avg
7.89x
3Y Avg
10.87x
5Y Avg
10.87x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $44.81M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $45.37M | N/A | 14.42x | 17.44x | 22.72x |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.20M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $44.16M | N/A | 7.89x | 10.87x | 10.87x |
| Lite Strategy, Inc. (LITS)vs › | $47.64M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $41.79M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.90M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $48.05M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $49.20M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
